Latham & Watkins Advises Novo on Financing of AMSilk

Latham & Watkins has advised Novo Holdings A/S (Novo) on a €25 million extended Series C financing for AMSilk GmbH (AMSilk), the world’s first industrial supplier of bio-fabricated silk protein materials. Novo is investing alongside existing investors ATHOS (AT Newtec) and MIG Capital. The financing will enable AMSilk to accelerate industrial scale and expand commercial operations of bio-engineered silk protein materials.

Latham & Watkins has already regularly advised Novo on a number of investments in the past, including Novo's first investment in AMSilk two years ago. The Series C financing of €29 million has now been extended to €54 million.

The Latham team was led by Hamburg partner Henning C. Schneider, with partner Dirk Kocher and associate Katarina Fröschle.